New diabetes drug SHR-3167 takes on insulin in Head-to-Head trial
NCT ID NCT06688123
First seen Nov 24, 2025 · Last updated May 07, 2026 · Updated 19 times
Summary
This study compares a new medicine, SHR-3167, with a standard insulin (insulin glargine) in 275 adults with type 2 diabetes who are not yet on insulin. Participants must be taking metformin (alone or with another drug) and have moderately high blood sugar. The main goal is to see which treatment better lowers HbA1c over 20 weeks, while also checking safety and other blood sugar measures.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, 210029, China
-
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, 200233, China
Conditions
Explore the condition pages connected to this study.